Hematologic malignancies, including leukemia, lymphoma, and multiple myeloma, continue to challenge clinicians with complex treatment regimens that often involve significant side effects and limited success, especially in advanced stages. Recent advancements in nuclear medicine have introduced theranostic strategies that merge diagnostic imaging with targeted therapeutic approaches, offering the potential for more precise and personalized treatment. A key area of progress lies in the development of alpha-emitting radiopharmaceuticals, such as225Ac,211At, or212Pb, which can deliver potent radiation directly to tumor cells, sparing healthy tissue and minimizing collateral damage. In parallel with these therapeutic advancements, molecular imaging using radiolabeled agents enables better disease monitoring, assessment of treatment efficacy, and personalized management of patients with hematologic malignancies. The integration of diagnostic imaging with radiotherapy allows for a more tailored approach, where treatment can be adjusted based on real-time information about tumor progression and response. This review examines the recent strides made in both the development of radiopharmaceuticals and their applications in molecular imaging, with a focus on the potential to improve precision, reduce toxicity, and optimize patient outcomes. The synergy between targeted therapy and molecular imaging represents a transformative shift in the management of hematologic malignancies. As these technologies evolve, they are poised to redefine treatment paradigms, offering new hope for patients and potentially improving survival rates with more effective and less toxic treatment options.
血液系统恶性肿瘤，包括白血病、淋巴瘤和多发性骨髓瘤，其复杂的治疗方案常伴随显著的副作用且疗效有限，尤其在晚期阶段，持续对临床医生构成挑战。核医学的最新进展引入了诊疗一体化策略，将诊断成像与靶向治疗方法相结合，为实现更精准和个性化的治疗提供了可能。其中，α粒子发射型放射性药物（如²²⁵Ac、²¹¹At或²¹²Pb）的开发是重要进展领域，这类药物能将强效辐射直接递送至肿瘤细胞，同时保护健康组织并减少附带损伤。与这些治疗进展同步，使用放射性标记剂的分子成像技术能够更好地监测疾病、评估治疗效果，并实现血液系统恶性肿瘤患者的个体化管理。诊断成像与放射治疗的整合使得治疗策略更具针对性，可根据肿瘤进展和治疗反应的实时信息进行调整。本综述探讨了放射性药物开发及其在分子成像应用方面的最新进展，重点关注其在提高精准性、降低毒性和优化患者预后方面的潜力。靶向治疗与分子成像的协同作用代表了血液系统恶性肿瘤管理模式的变革性转变。随着这些技术的发展，它们有望重新定义治疗范式，为患者带来新的希望，并通过更有效、毒性更低的治疗方案潜在地提高生存率。
Theranostics in Hematological Malignancies: Cutting-Edge Advances in Diagnosis and Targeted Therapy
肿瘤(癌症)患者之家